Omega Therapeutics Inc (OMGA): Rasio kapitalisasi pasar marang pendapatan
Omega Therapeutics is implementing a breakthrough platform for the precise tuning of gene expression without damaging DNA. The price-to-sales ratio dynamics correlate with these innovations, where 0.90 describes the current status of the metric. Risks are linked to fierce patent battles within the biotech sector; however, a stable staff of elite bioinformaticians and support from major partners provide the company with a sustainable technological advantage.
Omega (OMGA) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi bursa:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Omega Therapeutics|OMGA - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Omega Therapeutics Corp|OMGA - Gunggung utang perusahaan|Utang marang modal buku Omega|OMGA - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Omega Therapeutics|Indikator likuiditas cepet omegatherapeutics.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
OMGA - Bathi resik perusahaan|Prakiraan bathi perusahaan Omega Therapeutics|OMGA - Rasio rega marang bathi|Rasio prakiraan rega marang bathi Omega Therapeutics Inc|OMGA - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Omega|OMGA - Bathi operasional EBITDA|Bathi resik saben saham sajroning taun lumaku Omega Therapeutics|OMGA - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan omegatherapeutics.com|OMGA - Wutah bathi ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Omega Therapeutics
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:omegatherapeutics.com
Investors are assessing the resilience of Omega Therapeutics (OMGA) through the market capitalization-to-revenue ratio, which determines the valuation of each dollar of sales. By analyzing the fundamental P/S ratio, market expectations for the epigenomic platform can be compared with current revenues, accounting for the high risks associated with early-stage Pipeline assets and the mitigating influence of a partnership with a pharma behemoth.
Perusahaan pesaing
TEM - Rega marang dodolan|Rasio rega marang pendapatan Qiagen QGEN|Rasio kapitalisasi pasar marang pendapatan IONS|Repligen Corp. - Multiplikator P/S|RNA - Multiplikator P/S|CRISPR Therapeutics AG (CRSP) - Rasio rega marang pendapatan|Rasio rega marang dodolan WGS (genedx.com)|RARE (Ultragenyx) - Multiplikator P/S|Rega marang dodolan Beam Therapeutics Inc BEAM|Kapitalisasi marang pendapatan SRPT (Sarepta Therapeutics Inc)|Multiplikator P/S Twist Bioscience Corp (TWST)|10x Genomics, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan NTLA (intelliatx.com)|Stoke Therapeutics, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan BioLife Solutions Inc BLFS|WVE: Multiplikator P/S|Kapitalisasi marang pendapatan Maze Therapeutics Corp|Rasio rega marang pendapatan Sionna Therapeutics Inc|primemedicine.com (PRME) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Taysha Gene Therapies, Inc. (TSHA)|QURE - Rega marang dodolan|Rasio rega marang pendapatan MeiraGTx PLC MGTX|RGNX - Kapitalisasi marang pendapatan|Solid Biosciences Inc. - Multiplikator P/S|Multiplikator rega marang pendapatan ocugen.com (OCGN)|PACB: Multiplikator P/S|Benitec Biopharma Inc (BNTC) - Multiplikator P/S|DSGN (Design Pharma) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan RCKT (Rocket Corp)|Rasio rega marang pendapatan 4D Molecular Therapeutics (FDMT)|lexeotx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S KRRO (Korro Bio)|Multiplikator P/S Editas Medicine Inc EDIT|SLN - Rasio rega marang pendapatan|Rega marang dodolan ProQR Therapeutics N.V.|codexis.com (CDXS) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan sangamo.com|NAUT (Nautilus Biotechnology, Inc.) - Multiplikator P/S|Rega marang dodolan Metagenomi Inc. MGX|Multiplikator P/S DTIL|generationbio.com (GBIO) - Multiplikator rega marang pendapatan|Multiplikator P/S BOLD (Boundless Bio, Inc.)|Multiplikator P/S Exicure Inc. XCUR|IMNN: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PHIO (Phio Pharmaceuticals)|MBIO (mustangbio.com) - Kapitalisasi marang pendapatan|RNAZ: Kapitalisasi marang volume dodolan|BNGO (Bionano Genomics Inc.) - Multiplikator P/S|APDN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S BLUE|IPA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics Systems Inc OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals - Multiplikator P/S|TBIO - Multiplikator P/S|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Rasio rega marang dodolan UBX (Unity Biotechnology Inc.)
